Brief: Intensity Therapeutics Inc Int230-6 Achieved 100% Complete Response Rate In Preclinical Models Of Malignant Peripheral Nerve Sheath Tumors
30/06/2025 13:23
Intensity Therapeutics Inc INTS.O: INTENSITY THERAPEUTICS INC: INT230-6 ACHIEVED 100% COMPLETE RESPONSE RATE IN PRECLINICAL MODELS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMORS Source text: ID:nPn9WsjFWa Further company coverage: INTS.O
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing